April 28, 2025- Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development.
The new CHO K-1 cell line is able to deliver up to 8g/L, providing higher protein expression levels and increased stability, allowing customers to achieve greater productivity from pre-clinical phases through commercial development.